Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, NE, United States; Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States.
Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, NE, United States; Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States.
Int Immunopharmacol. 2018 Mar;56:113-118. doi: 10.1016/j.intimp.2018.01.022. Epub 2018 Feb 2.
To compare anti-malondialdehyde-acetaldehyde (MAA) antibody concentrations between rheumatoid arthritis (RA) patients and healthy and rheumatic disease controls.
Anti-MAA antibody (IgA, IgM, IgG) was measured using ELISA and banked serum from patients with RA (n = 284), osteoarthritis (OA, n = 330), spondyloarthropathy (SpA, n = 50), and systemic lupus erythematosus (SLE, n = 88) as well as healthy controls (n = 82). Anti-MAA antibody concentrations and the frequency of positivity were compared across groups. Multivariable linear regression analysis limited to RA and OA patients (due to sample size and data availability) was used to identify factors associated with anti-MAA antibody concentrations.
Although RA patients demonstrated among the highest circulating concentrations across isotypes, only IgA anti-MAA antibody was significantly higher than all other groups (p ≤ 0.02). Proportions (7% to 74%) of OA and SLE (less so for SpA) samples were positive for anti-MAA antibody, limiting the discriminatory capacity of anti-MAA antibody in RA (positive in 18% to 80%). In analyses limited to those with RA or OA, factors associated with higher anti-MAA antibody concentrations included RA case status, younger age (IgM), male sex (IgG), African American race (IgA, IgG) and current smoking (IgA). C-reactive protein levels and comorbidities were not associated with anti-MAA antibody concentrations.
With the possible exception of the IgA isotype, serum anti-MAA antibodies measured with currently available assays do not appear to adequately discriminate RA from other rheumatic conditions. With the identification of specific proteins that are MAA-modified in diseased tissues and requisite assay refinement, anti-MAA antibody holds potential promise as a biomarker in RA.
比较类风湿关节炎（RA）患者与健康对照和风湿性疾病对照者的抗丙二醛-乙醛（MAA）抗体浓度。
采用 ELISA 法检测 RA（n=284）、骨关节炎（OA，n=330）、脊柱关节炎（SpA，n=50）和系统性红斑狼疮（SLE，n=88）患者及健康对照者（n=82）的抗 MAA 抗体（IgA、IgM、IgG）。比较各组间抗 MAA 抗体浓度和阳性率。由于样本量和数据可用性的限制，对 RA 和 OA 患者进行多变量线性回归分析，以确定与抗 MAA 抗体浓度相关的因素。
尽管 RA 患者各型循环浓度最高，但只有 IgA 抗 MAA 抗体显著高于其他所有组（p≤0.02）。OA 和 SLE（SpA 较少）样本的抗 MAA 抗体阳性率（7%至 74%），限制了抗 MAA 抗体在 RA 中的鉴别能力（阳性率为 18%至 80%）。在仅包括 RA 或 OA 患者的分析中，与较高抗 MAA 抗体浓度相关的因素包括 RA 病例状态、年龄较小（IgM）、男性（IgG）、非裔美国人种族（IgA、IgG）和当前吸烟（IgA）。C 反应蛋白水平和合并症与抗 MAA 抗体浓度无关。
除 IgA 同种型外，目前可用的检测方法测量的血清抗 MAA 抗体似乎不能充分区分 RA 与其他风湿性疾病。随着对疾病组织中被 MAA 修饰的特定蛋白的鉴定和必要的检测方法改进，抗 MAA 抗体作为 RA 的生物标志物具有潜在的前景。
